300233SZSE
🚨 Material Event

Announcement on Subsidiary Receiving Drug Registration Certificate

✨ AI Summary

Shandong Jincheng Pharmaceutical Group announced that its wholly-owned subsidiary, Beijing Jincheng Taier Pharmaceutical Co., Ltd., has received a Drug Registration Certificate for "Inosine Adenosine Disuccinate for Injection." This product is deemed to have passed the consistency evaluation for generic drugs. The certificate further enriches the company's product pipeline and market presence in the digestive system treatment field.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300233

Securities Abbreviation: Jincheng Pharmaceutical

Announcement No.: 2026-050

Shandong Jincheng Pharmaceutical Group Co., Ltd.

Announcement on Subsidiary Receiving Drug Registration Certificate

The company and all members of the board of directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or major omissions.

Beijing Jincheng Taier Pharmaceutical Co., Ltd. (hereinafter referred to as "Jincheng Taier"), a wholly-owned subsidiary of Shandong Jincheng Pharmaceutical Group Co., Ltd., recently received the "Drug Registration Certificate" for "Inosine Adenosine Disuccinate for Injection" issued by the National Medical Products Administration. This product is deemed to have passed the consistency evaluation for generic drugs. The main contents are announced as follows:

I. Main Contents of the Certificate

Sign in to read the full translation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.